JP2011200238A5 - - Google Patents

Download PDF

Info

Publication number
JP2011200238A5
JP2011200238A5 JP2011106343A JP2011106343A JP2011200238A5 JP 2011200238 A5 JP2011200238 A5 JP 2011200238A5 JP 2011106343 A JP2011106343 A JP 2011106343A JP 2011106343 A JP2011106343 A JP 2011106343A JP 2011200238 A5 JP2011200238 A5 JP 2011200238A5
Authority
JP
Japan
Prior art keywords
cell
sirna molecule
sirna
nucleotides
overhang
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011106343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011200238A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011200238A publication Critical patent/JP2011200238A/ja
Publication of JP2011200238A5 publication Critical patent/JP2011200238A5/ja
Pending legal-status Critical Current

Links

Images

JP2011106343A 2003-07-03 2011-05-11 Ｓｙｋキナーゼ発現の阻害 Pending JP2011200238A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48429903P 2003-07-03 2003-07-03
US60/484,299 2003-07-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006517793A Division JP2007524397A (ja) 2003-07-03 2004-07-01 Ｓｙｋキナーゼ発現の阻害

Publications (2)

Publication Number Publication Date
JP2011200238A JP2011200238A (ja) 2011-10-13
JP2011200238A5 true JP2011200238A5 (https=) 2012-08-09

Family

ID=34079054

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006517793A Withdrawn JP2007524397A (ja) 2003-07-03 2004-07-01 Ｓｙｋキナーゼ発現の阻害
JP2011106343A Pending JP2011200238A (ja) 2003-07-03 2011-05-11 Ｓｙｋキナーゼ発現の阻害

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006517793A Withdrawn JP2007524397A (ja) 2003-07-03 2004-07-01 Ｓｙｋキナーゼ発現の阻害

Country Status (7)

Country Link
US (3) US7173015B2 (https=)
EP (2) EP1692153A4 (https=)
JP (2) JP2007524397A (https=)
CN (2) CN100577680C (https=)
AU (1) AU2004257167B2 (https=)
CA (1) CA2531069A1 (https=)
WO (1) WO2005007623A2 (https=)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE452906T1 (de) * 2000-04-13 2010-01-15 Thomas N Wight Therapeutische zusammenfassungen und verfahren zur modulierung von v3, eine isoform von versican
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
CA2546074A1 (en) * 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
EP1789447B1 (en) 2004-08-16 2012-04-25 Immune Disease Institute, Inc. Method of delivering rna interference and uses thereof
CN102600480B (zh) 2005-01-07 2015-07-22 阿尔尼拉姆医药品有限公司 RSV的RNAi调节及其治疗应用
WO2006113743A2 (en) * 2005-04-18 2006-10-26 Massachusetts Institute Of Technology Compositions and methods for rna interference with sialidase expression and uses thereof
TW201336514A (zh) * 2006-04-13 2013-09-16 Alcon Res Ltd ＲＮＡ干擾（ＲＮＡｉ）所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用（二）
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
JP2010527914A (ja) * 2007-04-26 2010-08-19 クォーク ファーマシューティカルズ インコーポレーティッド 呼吸器系への抑制性核酸分子の治療的送達
WO2009033027A2 (en) * 2007-09-05 2009-03-12 Medtronic, Inc. Suppression of scn9a gene expression and/or function for the treatment of pain
EP2217249A4 (en) * 2007-11-06 2011-10-12 Benaroya Res Inst INHIBITION OF VERSICAN WITH SIRNA AND OTHER MOLECULES
NZ585784A (en) * 2007-12-13 2012-09-28 Alnylam Pharmaceuticals Inc siRNAs for the treatment and prevention of respiratory syncytial virus (RSV) infection
US8691971B2 (en) 2008-09-23 2014-04-08 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating RNA interference
EP2350277A1 (en) * 2008-10-23 2011-08-03 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
CA2789276A1 (en) * 2010-02-09 2011-08-18 Drexel University New signaling molecule involved in ultraviolet damage to skin
KR101223483B1 (ko) * 2010-09-10 2013-01-17 한국과학기술연구원 전하결합 및 생분해성 공유결합으로 동시에 연결된 고분자―ｓｉＲＮＡ 나노입자 전달체
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2914284A1 (en) 2013-05-30 2014-12-04 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US20160244452A1 (en) 2013-10-21 2016-08-25 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015131080A1 (en) 2014-02-28 2015-09-03 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015164605A1 (en) * 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
CN117088931A (zh) 2014-08-12 2023-11-21 莫纳什大学 定向淋巴的前药
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
TWI788655B (zh) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
TWI707852B (zh) 2015-09-02 2020-10-21 美商林伯士拉克許米公司 Tyk2 抑制劑及其用途
US11738087B2 (en) 2015-09-08 2023-08-29 Monash University Lymph directing prodrugs
US10683308B2 (en) 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
AU2016342027B2 (en) 2015-10-23 2021-05-13 Navitor Pharmaceuticals, Inc. Modulators of Sestrin-GATOR2 interaction and uses thereof
EP3389664A4 (en) 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
EP4234552A3 (en) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
DK3426243T3 (da) 2016-03-09 2021-07-19 Raze Therapeutics Inc 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
US10323036B2 (en) 2016-10-14 2019-06-18 Nimbus Lakshmi, Inc. TYK2 inhibitors and uses thereof
EP3528816A4 (en) 2016-10-21 2020-04-08 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
WO2018089499A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
US11091451B2 (en) 2016-12-05 2021-08-17 Raze Therapeutics, Inc. SHMT inhibitors and uses thereof
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
TW202515876A (zh) 2017-03-08 2025-04-16 日商武田藥品工業股份有限公司 Tyk2抑制劑及其用途
EP3375784A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aza-dihydro-acridone derivatives
EP3375778A1 (en) 2017-03-14 2018-09-19 Artax Biopharma Inc. Aryl-piperidine derivatives
WO2018191146A1 (en) 2017-04-10 2018-10-18 Navitor Pharmaceuticals, Inc. Heteroaryl rheb inhibitors and uses thereof
PL3615019T3 (pl) 2017-04-26 2026-01-19 Navitor Pharmaceuticals, Inc. Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
SI3658557T1 (sl) 2017-07-28 2024-10-30 Takeda Pharmaceutical Company Limited Zaviralci TYK2 in njihova uporaba
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
WO2019034866A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
CA3077739A1 (en) 2017-08-29 2019-03-07 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
EP3727362A4 (en) 2017-12-19 2021-10-06 PureTech LYT, Inc. MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
JP7229257B2 (ja) 2018-01-29 2023-02-28 メルク パテント ゲーエムベーハー Ｇｃｎ２阻害剤およびその使用
BR112020015396A2 (pt) 2018-01-29 2020-12-08 Merck Patent Gmbh Inididores de gcn2 e usos dos mesmos
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
EP3759086A1 (en) 2018-02-27 2021-01-06 Artax Biopharma Inc. Chromene derivatives as inhibitors of tcr-nck interaction
ES2969982T3 (es) 2018-04-24 2024-05-23 Vertex Pharma Compuestos de pteridinona y usos de los mismos
HRP20241163T1 (hr) 2018-04-24 2024-11-22 Merck Patent Gmbh Antiproliferacijski spojevi i njihova uporaba
WO2019241789A1 (en) 2018-06-15 2019-12-19 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
CN113271940A (zh) 2018-10-15 2021-08-17 林伯士拉克许米公司 Tyk2抑制剂和其用途
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3870158A4 (en) 2018-10-24 2022-08-10 Navitor Pharmaceuticals, Inc. Polymorphic compounds and uses thereof
CA3120866A1 (en) 2018-11-30 2020-06-04 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CA3119773A1 (en) 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
CN113348021B (zh) 2019-01-23 2025-07-11 武田药品工业株式会社 Tyk2抑制剂和其用途
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
SG11202110828UA (en) 2019-04-02 2021-10-28 Bicycletx Ltd Bicycle toxin conjugates and uses thereof
CN120574283A (zh) 2019-04-05 2025-09-02 凯麦拉医疗公司 Stat降解剂和其用途
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
US11845724B2 (en) 2019-09-11 2023-12-19 Vincere Biosciences, Inc. USP30 inhibitors and uses thereof
MX2022002877A (es) 2019-09-13 2022-08-08 Nimbus Saturn Inc Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
US11723890B2 (en) 2019-11-01 2023-08-15 Navitor Pharmaceuticals, Inc. Methods of treatment using an mTORC1 modulator
AU2020397938A1 (en) 2019-12-05 2022-06-23 Janssen Pharmaceutica Nv Rapamycin analogs and uses thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
EP4081308A4 (en) 2019-12-23 2024-01-24 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
IL295362A (en) 2020-02-05 2022-10-01 Puretech Lyt Inc Lipid drug inhibitors of neurosteroids
TW202146393A (zh) 2020-03-03 2021-12-16 美商皮克醫療公司 Eif4e抑制劑及其用途
KR20230005160A (ko) 2020-03-19 2023-01-09 카이메라 쎄라퓨틱스 인코포레이티드 Mdm2 분해제 및 이의 용도
JP2023524679A (ja) 2020-04-30 2023-06-13 フィジーン、エルエルシー 癌線維芽細胞を標的化するための免疫療法の方法および組成物
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
WO2022019920A1 (en) 2020-07-24 2022-01-27 Verastem, Inc. Treatment of cancers using pi3 kinase isoform modulators
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
CA3186504A1 (en) 2020-08-17 2022-02-24 Stephen J. Blakemore Bicycle conjugates specific for nectin-4 and uses thereof
US12331046B2 (en) 2020-10-23 2025-06-17 Nimbus Clotho, Inc. CTPS1 inhibitors and uses thereof
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3200814A1 (en) 2020-12-02 2022-06-09 Alfredo C. Castro Tead inhibitors and uses thereof
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
MX2023009060A (es) 2021-02-02 2023-09-29 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
US12378229B2 (en) 2021-02-02 2025-08-05 Liminal Biosciences Limited GPR84 antagonists and uses thereof
EP4291235A4 (en) 2021-02-12 2025-01-08 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
WO2022213062A1 (en) 2021-03-29 2022-10-06 Nimbus Saturn, Inc. Hpk1 antagonists and uses thereof
US12325697B2 (en) 2021-04-09 2025-06-10 Nimbus Clio, Inc. CBL-B modulators and uses thereof
WO2022221866A1 (en) 2021-04-16 2022-10-20 Ikena Oncology, Inc. Mek inhibitors and uses thereof
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
CA3229560A1 (en) 2021-08-25 2023-03-02 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
US12157732B2 (en) 2021-08-25 2024-12-03 PIC Therapeutics, Inc. eIF4E inhibitors and uses thereof
WO2023034870A2 (en) 2021-09-01 2023-03-09 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing dmpk expression
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof
KR20250056924A (ko) 2022-08-02 2025-04-28 리미널 바이오사이언시스 리미티드 치환된 피리돈 gpr84 길항제 및 이의 용도
US20260028330A1 (en) 2022-08-02 2026-01-29 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
IL318577A (en) 2022-08-02 2025-03-01 Liminal Biosciences Ltd ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES
WO2024112894A1 (en) 2022-11-22 2024-05-30 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
AU2024312190A1 (en) 2023-06-23 2025-07-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
AU2024344754A1 (en) 2023-09-21 2026-04-02 Takeda Pharmaceutical Company Limited Tyk2 inhibitors for use in the treatment of inflammatory bowel disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5256555A (en) 1991-12-20 1993-10-26 Ambion, Inc. Compositions and methods for increasing the yields of in vitro RNA transcription and other polynucleotide synthetic reactions
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
US5939262A (en) 1996-07-03 1999-08-17 Ambion, Inc. Ribonuclease resistant RNA preparation and utilization
US6057134A (en) 1996-10-07 2000-05-02 Ambion, Inc. Modulating the efficiency of nucleic acid amplification reactions with 3' modified oligonucleotides
US6111086A (en) 1998-02-27 2000-08-29 Scaringe; Stephen A. Orthoester protecting groups
US20030084471A1 (en) 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
EP1272630A2 (en) * 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
ES2336887T5 (es) 2000-03-30 2019-03-06 Whitehead Inst Biomedical Res Mediadores de interferencia por ARN específicos de secuencias de ARN
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
JP2004536800A (ja) * 2001-05-09 2004-12-09 アルカベロ アクチェセルスカプ Ｔｈ１／ｔｈ２比を変調することによりｔｈ１及びｔｈ２細胞関連疾患を予防又は治療するための医薬組成物
EP1415156B1 (en) 2001-07-10 2009-09-02 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of multiple proteins in single cells
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
US20050130117A1 (en) 2001-10-03 2005-06-16 Davis Cong L. Modulators of lymphocyte activation and migration
US7371736B2 (en) 2001-11-07 2008-05-13 The Board Of Trustees Of The University Of Arkansas Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss
US7308364B2 (en) 2001-11-07 2007-12-11 The University Of Arkansas For Medical Sciences Diagnosis of multiple myeloma on gene expression profiling
US7894992B2 (en) 2001-11-07 2011-02-22 Board Of Trustees Of The University Of Arkansas Diagnosis and classification of multiple myeloma
US20060141493A1 (en) 2001-11-09 2006-06-29 Duke University Office Of Science And Technology Atherosclerotic phenotype determinative genes and methods for using the same
US20040018522A1 (en) 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
ATE525398T1 (de) 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20060127385A1 (en) 2002-12-06 2006-06-15 The Trustees Of Boston University Method for sustaining enos activity
JP2006524035A (ja) 2002-12-26 2006-10-26 シーマインズ リミテッド ライアビリティ カンパニー 癌の診断、予後診断および治療のための方法および組成物
CA2514986A1 (en) 2003-02-05 2004-08-19 Applied Research Systems Ars Holding N.V. Mucin-like polypeptides
US20050147593A1 (en) 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
EP1692258A4 (en) 2003-11-12 2007-03-21 Xiao Xu REAL-TIME ELECTRONIC CELL DETECTION SYSTEMS FOR CELL-BASED TESTS
CA2546074A1 (en) 2003-11-14 2005-06-02 Yale University Syk-targeted nucleic acid interference
US20050153923A1 (en) 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
US20060058255A1 (en) 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma

Similar Documents

Publication Publication Date Title
JP2011200238A5 (https=)
EP4137161A1 (en) Method and drug for treating hurler syndrome
EP1670518B1 (en) Rna interference for the treatment of gain-of-function disorders
US7709456B2 (en) Modulation of gene expression by oligomers targeted to chromosomal DNA
EP2371835A1 (en) Inhibition of syk kinase expression
CN110484615B (zh) lncRNA在病毒性心肌炎中调控巨噬细胞极化的应用
US9045753B2 (en) siRNA molecule for inhibiting growth of melanin and application thereof
TW201336514A (zh) ＲＮＡ干擾（ＲＮＡｉ）所媒介之與脾酪胺酸激酶相關之發炎症狀的抑制作用（二）
CN108144061A (zh) microRNA-210抑制剂在制备治疗炎症性皮肤病药物上的应用
WO2005083083A2 (en) Materials and methods for treatment of allergic disease
Denovan-Wright et al. Unexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo
JP2023505737A (ja) Ｒ１２４ｈ突然変異を備えたトランスフォーミング増殖因子ベータ誘導遺伝子の短鎖干渉ｒｎａを使用したアレル特異的サイレンシング
Ahn et al. Constitutive expression of short hairpin RNA in vivo triggers buildup of mature hairpin molecules
CN112662671B (zh) 靶向SMN2启动子区甲基化位点nt-290所在区域的反义寡核苷酸
CN113454220B (zh) 针对人细胞间粘附分子1(icam-1)的反义药物
WO2021067613A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
CN112779252B (zh) 靶向SMN2启动子区MeCP2结合的关键甲基化区域的反义寡核苷酸
CN101892226A (zh) 一种抑制人脂肪细胞ACC基因表达的siRNA及其表达载体和应用
EP2843049B1 (en) Neuronal differentiation promoter
CN101875931B (zh) 抑制人膜铁转运蛋白辅助蛋白基因表达的siRNA重组慢病毒及应用
EP4247394A2 (en) Compositions and methods for suppressing msut2
WO2025139392A1 (zh) 抑制CTGF基因表达的siRNA及其用途
JP2024510010A (ja) 癌療法
US8361985B2 (en) Short hairpin RNA for gene knockdown of NR1 subunit of the N-methyl-D-aspartate receptor and its application on pharmaceutics
CN117866953A (zh) 靶向生长激素释放抑制激素基因的shRNA及其医药应用